A new drug combo is offering hope for men with advanced prostate cancer. Adding the targeted cancer drug niraparib to hormone therapy reduced the risk of prostate tumor growth and slowed symptom ...
The Bellmunt Risk Score can provide prognostic information on survival among patients with metastatic castration-resistant prostate cancer, new data suggest.
The Prostate Cancer Foundation (PCF) today announced the recipients of its 2025 Challenge Awards, providing over $12 million in funding for 12 multi-institutional, cross-disciplinary research teams ...
A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...
The addition of neoadjuvant Lutetium-177 (Lu-177) therapy to metastasis-directed stereotactic body radiation therapy (SBRT) more than doubled progression-free survival (PFS) in men with ...
Candel Therapeutics Inc (NASDAQ:CADL) is advancing plans to bring its lead cancer immunotherapy toward potential ...
Xtandi addition to ADT and radiation did not significantly improve MFS in the overall high-risk prostate cancer population. Patients with clinical N1 disease showed improved five-year MFS with Xtandi, ...
Novartis has shared detailed data showing its radioligand therapy Pluvicto could slow the progression of certain hormone-sensitive prostate cancers ahead of a planned application with the FDA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results